ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy

The European Medicines Agency recommended conditional marketing authorization for ImmunityBio's Anktiva (nogapendekin alfa inbakicept) in combination with BCG to treat BCG‑unresponsive non‑muscle invasive bladder cancer carcinoma in situ, based on a single‑arm trial of 100 adults that showed a 71% complete response rate, median response duration of about 27 months and responses up to 54+ months, with durability of 66% at 12 months and 42% at 24 months; ImmunityBio must provide ongoing post‑marketing safety and efficacy data. The conditional pathway reflects the EMA's judgment that early patient access outweighs limitations of single‑arm data, and the opinion will be sent to the European Commission for final EU approval. The development addresses a sizable unmet need—NMIBC comprises roughly 75% of the ~200,000 projected bladder cancer diagnoses in 2025—and ImmunityBio shares were reported up 2.74% to $2.25 at publication.

Analysis

The European Medicines Agency recommended conditional marketing authorization for ImmunityBio's Anktiva (nogapendekin alfa inbakicept) in combination with BCG to treat BCG-unresponsive non‑muscle invasive bladder cancer carcinoma in situ based on a single‑arm trial of 100 adults. The trial reported a 71% overall complete response rate, responses lasting up to 54+ months, an average response duration of approximately 27 months, a 12‑month responder rate of 66% and a 24‑month responder rate of 42%.

The recommendation uses the EMA's conditional pathway, which balances early patient access against limitations of single‑arm data and requires ImmunityBio to submit long‑term safety and efficacy post‑marketing results; the opinion will be forwarded to the European Commission for final EU approval. This follows a prior regulatory setback noted in the article—a FDA refusal‑to‑file for expanded use—highlighting differing regulatory outcomes across jurisdictions.

Clinically and commercially, the decision targets a meaningful unmet need: bladder cancer is projected to generate ~200,000 diagnoses in 2025 with ~75% (≈150,000) being NMIBC, the most common form. The single‑arm nature of the data is a material risk to durable label expansion and payer uptake, making post‑marketing commitments and real‑world durability central to value realization.

Market reaction was mutedly positive with IBRX shares up 2.74% to $2.25 at publication and sentiment metrics indicating modest upside; near‑term investor focus should be the European Commission outcome and the scope/timeline of required post‑marketing studies.

Key Decisions for Investors

• Consider a cautiously constructive stance on IBRX given the EMA backing and sizable addressable NMIBC population, but avoid large position increases until the European Commission grants final approval and post‑marketing conditions are clarified
• Monitor the European Commission decision, the detailed post‑marketing study requirements and timelines, and any updates on durability and safety data at 12–24+ months as these will determine commercial uptake and reimbursement prospects
• Maintain readiness to reduce exposure or hedge if the FDA position remains adverse or if confirmatory/long‑term data fail to demonstrate sustained benefit beyond the single‑arm trial